CD8A and neoplasm: Additional discussion of this topic is provided by Ott and Bhardwaj (8), who speculate how tumor cell death resulting from MAPK pathway inhibition might enhance cross-presentation by DC in BRAFV600 mutant melanoma patients, and by Palombo et al. (9), who describe various danger-associated molecular patterns (DAMPs) released during immunogenic cancer cell death that stimulate inflammatory DC to activate tumor-specific CD8+ T cell responses.